Nanode Therapeutics, Inc. — Department of Health and Human Services SBIR Phase I: 4
Nanode Therapeutics, Inc. — SBIR Phase I award from Department of Health and Human Services.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Health and Human Services in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $441,150. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code 4 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $441,150
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- 4
- Solicitation
- PHS-2022-1
- NAICS
- —
- Place of performance
- RI
- Period
- —
Description
To develop a new, safe, and efficacious non-viral gene delivery system crossing the blood-brain barrier (BBB) for gene therapy of Alzheimer’s Disease (AD).